REVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
REVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-14), Revelation Biosciences's share price is $0.36. Revelation Biosciences's Book Value per Share for the quarter that ended in Sep. 2024 was $0.62. Hence, Revelation Biosciences's PB Ratio of today is 0.58.
The historical rank and industry rank for Revelation Biosciences's PB Ratio or its related term are showing as below:
During the past 4 years, Revelation Biosciences's highest PB Ratio was 108.70. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Revelation Biosciences's average Book Value Per Share Growth Rate was -98.50% per year.
The historical data trend for Revelation Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
PB Ratio | - | - | 4.32 | 0.60 |
Revelation Biosciences Quarterly Data | |||||||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | 0.49 | 0.60 | 0.47 | 2.75 | 1.37 |
For the Biotechnology subindustry, Revelation Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Revelation Biosciences's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.36 | / | 0.623 | |
= | 0.58 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Revelation Biosciences (NAS:REVB) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Revelation Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
George F Tidmarsh | director, 10 percent owner | |
Lakhmir S Chawla | director | 1960 KIRBY ROAD, MCLEAN VA 22101 |
Axa Im Prime Impact Gp S.a.r.l | other: Former 10% owner | 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453 |
Axa Im Prime Impact Master Fund I Sca Sicav-raif | other: Former 10% Owner | 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453 |
Axa Investment Managers S.a. | other: Former 10% owner | 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800 |
Axa Investment Managers Paris | other: Former 10% owner | 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800 |
Axa Investment Managers Uk Ltd | other: Former 10% owner | 22 BISHOPGATE, LONDON X0 EC2M 3XJ |
S.a. Axa | other: Former 10% owner | 25 AVENUE MATIGNON, PARIS I0 75008 |
Jess Roper | director | 5555 OBERLIN DRIVE, SAN DIEGO CA 92121 |
James Rolke | director, officer: Chief Executive Officer | 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121 |
Curt H Labelle | director | C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011 |
Jennifer Carver | director | 725 NEWPORT STREET, DENVER CO 80220 |
Zygmont Chester Stanley Iii | officer: Chief Financial Officer | 3322 MILLIKIN AVE, SAN DIEGO CA 92122 |
Lawrence Feis | 10 percent owner | 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611 |
Feis Equities Llc | 10 percent owner | 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606 |
From GuruFocus
By Business Wire • 08-09-2024
By GuruFocus Research • 03-01-2024
By Business Wire • 03-12-2024
By Business Wire Business Wire • 05-22-2023
By Business Wire • 10-04-2023
By Business Wire Business Wire • 06-12-2023
By Business Wire • 01-23-2024
By Business Wire • 10-12-2023
By Business Wire • 12-02-2024
By Business Wire Business Wire • 01-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.